• Skip to main content
  • Skip to footer

Oklahoma Medical Research Foundation | OMRF

OMRF is an independent, nonprofit biomedical research institute dedicated to discoveries that make a difference.

  • About
    • General Information
    • Disease Research
    • Education & Outreach
    • Events
    • Jobs
    • Contact Us
  • Science
    • Scientist Directory
    • Research Programs
    • Research Centers
    • Core Facilities
    • Scientific Publications
    • Scientific Seminars
    • Technology Ventures
  • News
    • Media Resources
    • OMRF in the Media
    • OMRF News
    • OMRF Publications
    • OMRF Videos
    • Dr. Prescott’s Columns
  • Patients
    • Lupus (SLE)
    • MBTPS1 Related Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjögren’s Syndrome
    • Other Autoimmune Disorders
  • Donate
    • Donate Now
    • Tax Credit
    • Planned Giving
    • Vehicle Donations
    • Why We Give
    • Your Gift at Work
    • Donor Recognition
    • Contact
  • My 101
  • Research
  • Brief CV
  • Publications
  • Contact
  • Lab Staff
  • Lab Website
  • News
Home - Science - Scientist Directory - Guthridge, Joel

Joel Guthridge, Ph.D.

Assistant Member
Arthritis & Clinical Immunology Research Program

← Back

My 101

My laboratory research focuses on understanding mechanisms that contribute to the development and progression of human autoimmune diseases. We expand upon more than 20 years of pioneering genetic work done at OMRF that defined what and which genes contribute to a patient’s risk to develop an autoimmune disease. Now we focus on understanding how those genes work, the mechanisms that are changed in one’s cells that lead eventually to autoimmunity.

It is imperative that we better understand the underlying causes and progression of systemic autoimmune diseases like lupus, multiple sclerosis and others, and that task requires unraveling vast networks of interconnected immune responses. Our primary focus is defining, at a systems level, the pathways that influence the regulation and development of autoimmune responses. Ultimately, this information can be used either to define pathways that contribute to disease characteristics in those patients, thereby identifying the drug targets for that subgroup of patients, or it can allow physicians to better predict the disease course of a patient, tailoring treatments to the individual’s unique profile.

All of our research revolves around interfacing with and pushing the limits of what we can do for the patients in OMRF’s clinics for lupus, multiple sclerosis, rheumatoid arthritis, Sjögren’s and other autoimmune conditions. Our ultimate goals are: 1) to improve patient care by helping create more accurate diagnostic tools and new methods to determine a person’s risk of developing a disease or predicting how individuals will respond to certain medications, and 2) to understand molecular pathways that contribute to the development or progression of the disease, and thereby identify potential new drug targets that will help treat these devastating diseases.

 

Research

My research focuses on understanding the etiology and pathogenesis of systemic autoimmune diseases. This requires unraveling vast networks of interconnected immune responses, a task that exceeds the limitations of traditional laboratory methods. My group applies high-throughput/high-content, precision medicine approaches to this problem. Our primary focus is defining, at a systems level, the pathways that influence the regulation and development of autoimmune responses.

I was involved in some of the early candidate gene association studies, and then in the whole genome association studies in lupus. I have also been intimately involved with large consortium studies and many follow-up fine mapping studies through my management of several large collections of lupus samples and data in the OMRF Biorepository and Sample Procurement Core. These results led to studies on the functional effects of disease-associated genetic variants, particularly in genes affecting the complement regulatory proteins/receptors, innate immune responses, and B cell signaling pathways.

To gain a high-level view of immune function in patients with autoimmune disease, we use a systems biology approach to combine data from our genetic/genomic studies, innovative biomarker assessments, cellular immunophenotyping experiments, and single cell proteomics analyses. Because multiple immune pathways can lead to the same autoimmune disease diagnosis, we also use these multidimensional datasets and associated clinical data to cluster patient subpopulations and model altered pathways in various populations. We apply these methods both in translational studies of cross-sectional and longitudinal autoimmune disease cohorts, and in investigator-initiated clinical trials. The ultimate goal of this work is to enable more accurate diagnosis, risk assessment before clinical disease onset, and prediction of therapeutic responses in order to improve patient care.

Brief CV

B.S., University of Iowa, Iowa City, IA, 1985
Ph.D., University of Kentucky, Lexington, KY, 1992
Postdoc, University of Colorado Health Sciences Center, Denver, CO, 1996
MSCIS, Regis University, Denver, CO

Joined OMRF Scientific Staff in 2018

Publications

Recent Publications

Ortiz Fernández L, Coit P, Yilmaz V, Yentür SP, Alibaz-Oner F, Aksu K, Erken E, Düzgün N, Keser G, Cefle A, Yazici A, Ergen A, Alpsoy E, Salvarani C, Casali B, Kısacık B, Kötter I, Henes J, Çınar M, Schaefer A, Nohutcu RM, Zhernakova A, Wijmenga C, Takeuchi F, Harihara S, Kaburaki T, Messedi M, Song YW, Kaşifoğlu T, Carmona FD, Guthridge JM, James JA, Martin J, González Escribano MF, Saruhan-Direskeneli G, Direskeneli H, Sawalha AH. Genetic association of a gain of function interferon gamma receptor 1 (IFNGR1) polymorphism and the intergenic region LNCAROD/DKK1 with Behçet's disease. Arthritis Rheumatol, 2021 January, PMID: 33393726

Raj P, Song R, Zhu H, Riediger L, Jun DJ, Liang C, Arana C, Zhang B, Gao Y, Wakeland BE, Dozmorov I, Zhou J, Kelly JA, Lauwerys BR, Guthridge JM, Olsen NJ, Nath SK, Pasare C, van Oers N, Gilkeson G, Tsao BP, Gaffney PM, Gregersen PK, James JA, Zuo X, Karp DR, Li QZ, Wakeland EK. Deep sequencing reveals a DAP1 regulatory haplotype that potentiates autoimmunity in systemic lupus erythematosus. Genome Biol 21:281, 2020 November, PMID: 33213505, PMCID: PMC7677828

Farris AD, Guthridge JM. Overlapping B cell pathways in severe COVID-19 and lupus. Nat Immunol, 2020 November, PMID: 33139917

Selected Publications

Lu R, Munroe ME, Guthridge JM, Bean KM, Fife DA, Chen H, Slight-Webb SR, Keith MP, Harley JB, James JA. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun. Nov;74:182-193. PMID: 27338520 PMCID: PMC5079766

Slight-Webb S, Lu R, Ritterhouse LL, Munroe ME, Maecker HT, Fathman CG, Utz PJ, Merrill JT, Guthridge JM, James JA. 2016. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. Arthritis Rheumatol. Oct;68(10):2492-502. PMID: 27059145 PMCID: PMC5042816

Dozmorov I, Dominguez N, Sestak AL, Robertson JM, Harley JB, James JA, Guthridge JM. 2013. Evidence of dynamically dysregulated gene expression pathways in hyperresponsive B cells from African American lupus patients. PLoS One. 8(8):e71397. PMID: 23977035 PMCID: PMC3744560

Guo L, Deshmukh H, Lu R, Vidal GS, Kelly JA… and Guthridge JM. 2009. Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population. Genes Immun 10(5):531-8. PMID: 19339986 PMCID: PMC2736873

The International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN) , Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO… Guthridge JM, et al. 2008. Genome-wide association scan in women with systemic lupus erythematosus identifies risk variants in ITGAM, PXK KIAA1542 and other loci. Nat Genet. 40(2):204-10. PMID: 18204446 PMCID: PMC3712260

Nath SK, Han S, Kim-Howard X, Kelly JA, Viswanathan P… Guthridge JM*, and Harley JB*. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet. 2008;40(2):152-4. (*authors contributed equally) PMID: 18204448

 

Contact

Arthritis & Clinical Immunology Research Program, MS 53
Oklahoma Medical Research Foundation
825 N.E. 13th Street
Oklahoma City, OK 73104

Phone: (405) 271-2600
Fax: (405) 271-7063
E-mail: Joel-Guthridge@omrf.org

Lab Staff

Miles Smith, Ph.D.
Bioinformatics Scientist

Caleb Marlin, Ph.D.
Project Manager

Marci Beel
Research Assistant

Tate Bolin
Senior Research Technician

Kelly Gross
Research Technician

Christian Wright
Research Technician

Joseph Kheir
Data Analyst

News from the Guthridge lab

Dr. Guthridge in the Media

News from the Guthridge lab

Dr. Guthridge in the Media

Researchers gain better understanding of lupus
MuskogeePhoenix.com

Business people: OMRF announces promotions
Oklahoman.com

Lupus treatments can be tailored to patient's individual cells, study shows
CheckOrphan.org

Testing individual cells to guide treatment
BrightSurf.com

Lupus treatments can be tailored to patient's individual cells
MoneySavvyLiving.com

New OMRF findings pave way for better lupus treatments
EdmondSun.com

OMRF reports more effective lupus treatments
JournalRecord.com

Oklahoma business briefs: OMRF researchers win grants to study lupus
NewsOk.com

OMRF awarded grants to study lupus genes
JournalRecord.com

One of the coldest places in Oklahoma also holds precious medical science
KFOR.com

Before Footer

EEO/AA Employer/Vet/Disabled

Footer

  • Jobs
  • Directory
  • Donor Privacy Statement
  • Intranet
Charity navigator
United Way Give Smart OKC
Facebook Twitter YouTube Instagram Mail Linkedin
Administrator Log In